Alternative Biomedical Solutions (ABS) announced today that Elizabeth Bell has been appointed to the position of LCMS BDE. Ms. Bell will be focused on the cannabis segment as well as supporting ABS’ full-line BDEs for confirmation testing opportunities.
Alternative Biomedical Solutions (ABS) announced today that Elizabeth Bell has been appointed to the position of LCMS BDE. Ms. Bell will be focused on the cannabis segment as well as supporting ABS’ full-line BDEs for confirmation testing opportunities.
Alternative Biomedical Solutions (ABS) announced today that Adrian Whipple has been appointed to the position of Chief Financial Officer. Mr. Whipple will be responsible for accounting, financial planning and analysis, treasury, tax, business operations and M&A analysis.
Alternative Biomedical Solutions (ABS) announced today that Adrian Whipple has been appointed to the position of Chief Financial Officer. Mr. Whipple will be responsible for accounting, financial planning and analysis, treasury, tax, business operations and M&A analysis.
We are bullish on our outlook for the Core Segments for the year ahead and much of it is due to the groundwork that Chris has put in place. It’s been great to have him on our team.
Partnership compliments each company’s strengths and segment expertise to service key markets in Toxicology and Cannabis segments
Partnership compliments each company’s strengths and segment expertise to service key markets in Toxicology and Cannabis segments
Alternative Biomedical Solutions (ABS) announced today the promotion of Yuran Li to Director of MS Commercial Strategies.
Alternative Biomedical Solutions (ABS) announced today the addition of Sue Milo, Business Development Executive.
Alternative Biomedical Solutions (ABS) announced today the launch of its new corporate website
Alternative Biomedical Solutions (ABS) announced today the additon of Rashid Hussain, Business Development Executive
Introducing Yuran Li, MT ASCP, Business Development Executive